ASX:CYP Cynata Therapeutics (CYP) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free CYP Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume159,853 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield13.95%Price TargetN/A Stock AnalysisStock Analysis Get Cynata Therapeutics alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Cynata TherapeuticsCynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. CYP Stock News HeadlinesApril 13, 2024 | investing.comCynata Therapeutics Ltd (CYP)April 8, 2024 | finanznachrichten.deCynata Therapeutics: Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical TrialApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 7, 2024 | finance.yahoo.comPatient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical TrialMarch 5, 2024 | finanznachrichten.deCynata Therapeutics: First Patient Treated in Phase 2 GvHD TrialFebruary 26, 2024 | finance.yahoo.comEncouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical TrialFebruary 8, 2024 | finance.yahoo.comCompanies Like Cynata Therapeutics (ASX:CYP) Could Be Quite RiskyJanuary 6, 2024 | morningstar.comCynata Therapeutics Ltd CYPApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 5, 2023 | finance.yahoo.comWe're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash BurnOctober 27, 2022 | yahoo.comStem Cells Market Size to be Worth $31.6 Billion by 2030 at CAGR of 11.4%: Grand View Research, Inc.June 23, 2022 | finance.yahoo.comHere's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn SituationMay 27, 2022 | yahoo.comAK-47 and Student ‘Hit List’ Found Destined for Another Texas School, District SaysDecember 29, 2021 | msn.comASX Health Stocks: Cynata signs deal with FujiFilm, set to produce MSC stem cells on a mass scaleNovember 9, 2021 | uk.finance.yahoo.comCynata Therapeutics Limited (CYP.AX)October 16, 2021 | finance.yahoo.comInvestors in Cynata Therapeutics (ASX:CYP) have unfortunately lost 47% over the last three yearsJuly 23, 2021 | barrons.comCynata Therapeutics Ltd.See More Headlines Receive CYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CYP CUSIPN/A CIKN/A Webwww.cynata.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.15% Return on Assets-52.45% Debt Debt-to-Equity RatioN/A Current Ratio9.69 Quick Ratio9.23 Sales & Book Value Annual Sales$2.40 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow11.93 Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares179,630,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.81 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Kilian KellyMD, CEO & DirectorDr. Jolanta AireyChief Medical OfficerMr. Peter Gordon Webse B.Bus (Age 61)FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary Comp: $140kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersKilian KellyBought 94,143 shares on 11/22/2023Total: $12,426.88 ($0.13/share)Paul WottonSold 220,000 sharesTotal: $26,400.00 ($0.12/share)Darryl MaherSold 25,000 sharesTotal: $3,375.00 ($0.14/share) CYP Stock Analysis - Frequently Asked Questions How were Cynata Therapeutics' earnings last quarter? Cynata Therapeutics Limited (ASX:CYP) posted its earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). What other stocks do shareholders of Cynata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cynata Therapeutics investors own include Starpharma (SPL), Rigel Pharmaceuticals (RIGL), Mesoblast (MSB) and Immutep (IMM). This page (ASX:CYP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
